Novartis's smokers' cough treatment gets European nod

ZURICH Mon Oct 1, 2012 1:33am EDT

An employee smokes a cigarette beside the logo of Swiss drugmaker Novartis AG in front of a plant in Basel October 25, 2011. REUTERS/Arnd Wiegmann

An employee smokes a cigarette beside the logo of Swiss drugmaker Novartis AG in front of a plant in Basel October 25, 2011.

Credit: Reuters/Arnd Wiegmann

Related Topics

ZURICH (Reuters) - Swiss drugmaker Novartis said on Monday the European Commission had approved its Seebri Breezhaler as a once-daily treatment for adult patients with chronic obstructive pulmonary disease, more commonly known as smoker's cough, in the European Union.

Trials showed that the treatment significantly improved lung function over the first four hours after morning dosing when compared to placebo, and that this benefit was sustained for 24 hours over a 52-week period, Novartis said.

The group said the treatment will be available to physicians and patients in some European Union markets by year end.

Deutsche Bank has estimated peak sales for Seebri Breezhaler at some $500 million.

(Reporting by Martin de Sa'Pinto)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
gregbrew56 wrote:
I’m hoping that before this new (and probably expensive) drug is made available to insured patients that the doctor verifies that the patient is no longer smoking cigarettes, if that was the cause.

The rest of us should not be required to pay higher insurance premiums to subsidize poor choices by other insured people.

Oct 01, 2012 11:43am EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.